At long last, the FDA has authorized 23andMe to market health-related genetic testing. It’s good news, but the impact of this is minimal for the time being. This specific authorization is for analysis of a single disease, but this “important first step” paves the way for the full suite of DNA analysis to return to the Mountain View-based genetics company.

After weeks of behind-the-scenes discussions with the FDA, 23andMe has just announced that it is suspending its genetic health analysis for new customers. Those of you who purchased DNA kits after November 21st will only receive the raw genetic data and ancestry analysis from 23andMe. Unfortunately, this means the utility of the company’s $99 DNA test is drastically reduced for the time being.